The burden of rotavirus disease in the Latin American region has been poorly understood despite the promise of effective vaccines. We describe here the implementation and results of a rotavirus surveillance network in the Latin American and Caribbean region. Rotavirus causes an estimated 527,000 deaths due to diarrhea among children !5 years of age annually, and 185% of this burden is in poor regions in Asia and
Africa [1] . Diarrhea-related mortality is very low in middle-to-high-income countries with better health care access and overall better-nourished populations; however, rotavirus disease remains a major cause of hospitalizations and outpatient clinic visits for severe diarrhea among children aged !5 years. Over the past 25 years, the development of rotavirus vaccines has been promoted as a means to prevent this burden. Two live, oral rotavirus vaccines have been commercially available since 2006: the monovalent human rotavirus vaccine (Rotarix [GlaxoSmithKline Biologicals]) and the pentavalent bovine-human reassortant vaccine (RotaTeq [Merck] ). Both vaccines have demonstrated good safety and efficacy profiles in large clinical trials conducted predominantly in developed countries and in Latin America [2, 3] .
On the basis of the results of these trials, the World Health Organization (WHO) has recommended the routine use of these vaccines in the Americas and Eu-rope [4] . By 2007, Brazil, Ecuador, El Salvador, Mexico, Nicaragua, Panama, and Venezuela had introduced 1 of the 2 rotavirus vaccines in their national programs [5] ; Bolivia introduced vaccine in 2008.
To inform a policy decision to introduce a rotavirus vaccine and to monitor the effect of a rotavirus immunization program, data on local disease burden and circulating strains is needed. However, until recently, the burden of rotavirus disease in the Latin American region was poorly understood, despite the promise of effective vaccines in the near future.
Most Latin American and Caribbean countries have diarrhea surveillance systems, but historically, they have lacked rotavirus diagnostic capacity and have used varying case definitions. A recent retrospective review examined studies performed during 1998-2002 in the Latin American region that included children who were hospitalized with diarrhea and found only 18 studies conducted in 8 separate countries; all of these studies used different diagnostics and involved different age groups [6] . Models used to assess the burden of rotavirus globally estimate that there are 15,000 deaths, 75,000 hospitalizations, 2 million clinic visits, and 10 million cases of rotavirus diarrhea annually in the Latin American region [1] . However, these calculations are based on data on the prevalence of rotavirus infection among children hospitalized for diarrhea from studies in countries with similar per capita income or mortality.
In 2004, with financial support from the Rotavirus Vaccine Program (funded by the GAVI Alliance; formerly known as the Global Alliance for Vaccines and Immunization) and the Sabin Institute and with technical support from the US Centers for Disease Control and Prevention (CDC), the Pan American Health Organization (PAHO) began implementation of a surveillance network for hospitalizations for diarrhea in Latin American and Caribbean countries with use of standardized definitions and diagnostics, in accordance with a generic protocol for surveillance [7] . The objectives of this network are to (1) better understand the burden and epidemiology of severe rotavirus disease, (2) describe the diversity of circulating strains of rotavirus in the region, (3) provide a platform to collect data for economic studies on rotavirus illness, and (4) monitor the impact of rotavirus vaccine introduction on burden and circulating strains of rotavirus, including possible serotype replacement. This article describes the elements of the network and presents analyses of epidemiologic and laboratory data collected at these sentinel sites from 2005 through 2007.
METHODS
The network was initially established in 2005 with 7 countries (Bolivia, El Salvador, Guatemala, Honduras, St. Vincent and the Grenadines, and Venezuela), and by 2007, 4 more countries were added (Chile, Nicaragua, Paraguay, and Suriname), for a total of 11 countries that are geographically and socioeconomically representative of the Latin American and Caribbean region. Sentinel hospital surveillance sites were selected in each country on the basis of several criteria, including (1) a welldefined geographical and demographic population, (2) at least 250-500 children aged !5 years per year who were admitted to a hospital for gastroenteritis, (3) adequate facilities for stool sample collection and handling and for rotavirus testing, and (4) institutional commitment to surveillance and provision of adequate human and logistic resources.
Surveillance at these sentinel hospital sites was instituted using PAHO surveillance guidelines for rotavirus [7] . This guideline includes standardized case definitions, screening and investigation procedures for children with diarrhea, laboratory procedures, and information on control and prevention measures for rotavirus disease. Countries received technical support from the PAHO and the CDC through site visits and regional and subregional meetings.
Trained study personnel screened hospitalized children to determine whether their case met the definition for a suspected case of rotavirus infection. A suspected case was defined as any case in a child aged !5 years who was hospitalized for acute diarrhea (у3 stools looser-than-normal within 24 h) lasting !14 days. Hospitalization was defined as any admission to the hospital, including emergency care room, for supervised rehydration. A standardized form was completed, and a whole stool specimen was collected. Stool specimens were stored at 2Њ-8ЊC at the hospital before testing. A confirmed case was a suspected case in a patient whose stool sample tested positive for rotavirus. Children were excluded from the study if they (1) had persistent vomiting without diarrhea; (2) were hospitalized primarily for reasons unrelated to diarrhea, even if they presented with diarrhea; (3) had the stool specimen collected 148 h after hospital admittance (to avoid including hospitalacquired diarrhea); or (3) had been referred to the study hospital after a hospitalization for diarrhea elsewhere after у24 h.
Laboratory testing. All countries used the same enzymelinked immunosorbent assay (IDEIA Rotavirus Oxoid; Ely Thermo Fisher Scientific) to test for rotavirus antigens in stool samples from patients with suspected cases. A sample of rotavirus-positive stool specimens from all countries was sent to the CDC (Atlanta, GA) for further characterization by previously described reverse-transcriptase polymerase chain reaction and nucleotide sequencing methods [8] [9] [10] [11] . For logistical and cost considerations, ∼10% of the rotavirus-positive specimens were submitted for genotyping. These specimens were selected on the basis of optical density and so that selection of samples from different areas of the country was ensured.
Data reporting and analysis. For the duration of surveillance, each country reported monthly to the PAHO the number of children aged !5 years who (1) were hospitalized for diarrhea, (2) met the case definition (ie, were eligible), (3) were enrolled and had a stool sample collected, and (4) had a confirmed rotavirus-positive sample. To evaluate the performance at each site and to minimize potential biases arising from partial enrollment, the percentage of eligible children who were enrolled in each country was determined, and a threshold of 80% was used as a performance target for each country. Subsequently, the percentage of enrolled children who were positive for rotavirus in each year was calculated. Because rotavirus is seasonal, the analysis of rotavirus epidemiology only included data from sites that reported at least 1 full year of data to include both high and low seasons. To estimate rotavirus-associated mortality in each country, we used WHO estimates of the number of deaths due to diarrhea in that country in 2004 [12] multiplied by the percentage of hospitalizations for diarrhea caused by rotavirus in that country; the estimate was compared with the estimates published by the WHO [1] . To evaluate seasonal patterns of disease, the numbers of eligible children and children with confirmed rotavirus disease during 2006-2007 in each country were plotted by month. The peak season was defined as 1 month or 2 consecutive months with the highest number of results positive for rotavirus. The onset of rotavirus season was defined as the first month that the percentage of results positive for rotavirus exceeded the yearly mean, and the duration of rotavirus season was defined as the number of months with positive results exceeding the mean [13] . guay enrolled у80% eligible children. Of the 10 countries that reported this information in 2007, 6 reached or exceeded an 80% enrollment rate (Figure 2) Rotavirus epidemiology. During January 2006-December 2007, 9 countries reported complete epidemiologic and laboratory data for the 2 entire years, and an additional 2 countries reported data for only 2007. During this 2-year period, data and stool samples were collected from a total of 19,817 children with suspected cases, 8141 of whom had samples positive for rotavirus. The median percentage of patients with rotaviruspositive samples, by country, was 31.5% (mean, 42%), ranging from 24% in Suriname to 47% in Guatemala (Table 1) .
RESULTS

Overall
In 2006, the median percentage of rotavirus-positive samples was 34.5% (mean, 41%), ranging from 18% in St. Vincent to 52% in Guatemala. No data by month were available for Suriname and St. Vincent and the Grenadines, and information for only part of 2007 was collected in Nicaragua; thus, these countries were not included in the analysis of seasonality. Two years of data were available for the remaining 8 countries, except for Chile, where data were only reported from 2007.
Marked seasonality in rotavirus disease was noted in all countries. As expected, the rotavirus season peaked from November through March in the Northern Hemisphere countries, and a reverse seasonality was evident in Southern Hemisphere countries from May through September. The most marked seasonality during 2006-2007 was observed in countries north of the equator (including El Salvador, Guatemala, Honduras, Venezuela, and Guyana), with rotavirus season peaking in February and March ( Figure 3A) . During the same period, in Guatemala, El Salvador, and Honduras, the rotavirus season started in November, January, and February, respectively. The season in Central America ends in El Salvador and Honduras in April. Venezuela had the longest rotavirus season (from October through April), with most activity reported in January (data not shown). The rotavirus season in countries south of the equator (Bolivia, Chile, and Paraguay) occurred from May through September ( Figure 3B ). In Bolivia, the peak was from May through June, and in Paraguay, it occurred in August, which explains the double peak apparent in Southern Hemisphere countries. In Chile, disease was prevalent throughout the year, with a small peak from May through June (data not shown).
In 2004, the estimated number of deaths due to diarrhea per country conducting surveillance ranged from 2720 (in Bolivia) to !1 (in St. Vincent and the Grenadines), and the number of deaths due to rotavirus disease ranged from 1225 (in Guatemala) to !1 (in St. Vincent and the Grenadines). The risk of a death due to rotavirus diarrhea among children aged !5 years was highest in low-income countries, such as Bolivia (1 of 1160 children), Guyana (1 of 1296), and Guatemala (1 of 1638). Overall, in the 10 countries for which we were able to perform this analysis, 3492 children die annually of rotavirus disease; this is equivalent to a mortality risk of 1 of 2874 children aged !5 years. Our results were similar to WHO estimates of 3416 deaths annually and a total risk of 1 death due to rotavirus disease among 2937 children aged !5 years in these countries (Table 2) . Rotavirus strains. Strain genotypes were evaluated for 388 rotavirus-positive specimens collected during 2005-2007 from 7 countries (El Salvador, Guatemala, Guyana, Honduras, Nicaragua, St. Vincent and the Grenadines, and Suriname). Overall, the 3 most prevalent strains detected were globally common rotavirus strains P [8] 
G1 (32%), P[8] G9 (20.9%), and P[4] G2 (18.3%). Other common strains were infrequently detected (P[8] G3 [1%] and P[8] G4 [5.4%])
. Several globally uncommon strains were also detected, including P[8] G8 (9.5%), P [6] G12 (0.8%), P[8] G2 (0.8%), P[6] G4 (0.3%), and P[6] G8 (0.3%). Mixed infections with common genotypes occurred in 4.4% of the specimens, and strains that could not be typed occurred in 6.4% (Table 3) .
DISCUSSION
Since 2005, a standardized surveillance network for severe rotavirus diarrhea requiring hospitalization among children !5 years of age has been established at 54 sites in 11 countries throughout Latin America and the Caribbean. This network has provided important evidence of the high burden of rota- virus disease in the region at a time when rotavirus vaccines are being introduced by Latin American and Caribbean countries. Data collected from 2006 and 2007 suggest that a median of 31.5% of all hospitalizations for diarrhea (3% of all hospitalizations among children !5 years of age in these countries) are attributable to rotavirus infection. Using these countryspecific data, we estimated that 1 of 2874 children will die of rotavirus disease by 5 years of age in these selected countries. These data closely reflect mortality estimates calculated by the WHO that were derived by extrapolation of data on rotavirus from countries with similar mortality among children aged !5 years, providing validation of this methodology. Of note, a wide disparity of mortality risk exists between the countries participating in the network, highlighting the potentially large impact that rotavirus vaccination could have on deaths due to diarrhea in the poorer countries of this region, as well as on hospitalizations for rotavirus diarrhea in all countries. It is encouraging that the rotavirus strain data collected from the network suggest that 175% of strains were globally common strains against which both current commercial vaccines have demonstrated good efficacy in trials in Latin American countries and elsewhere [2, 3, 14, 15] . However, there were few strains genotyped, and some unusual strains were also apparent, including G12 and G8 types in 10% of samples, although most of these were G8 combined with P [8] , a P type included in both commercial vaccines. The level and breadth of heterologous strain crossprotection afforded by the vaccines remain unclear and underline the importance of maintaining surveillance as vaccines are introduced.
The prevalence of rotavirus infection among children hospitalized with diarrhea varied considerably among countries and years, which could be explained by several reasons. First, the 3 countries that reported the lowest percentages of hospitalizations for rotavirus infection also reported the fewest overall data, and these low percentages may be attributable, in part, to artifacts of low and erratic enrollment during the year. Second, although the use of a standardized protocol should have prevented substantial surveillance biases overall, it remains possible that case definitions and exclusion criteria were applied differently at the point of enrollment. The proportion of all cases of diarrhea that were deemed to be eligible ranged from 52%-96%, which may suggest different enrollment criteria. For instance, a lower proportion of all cases of diarrhea considered to be eligible may suggest a bias toward cases with presentations suggestive of rotavirus disease (eg, no blood in stool or vomiting). However, no correlation of a low percentage of eligible cases with higher rotavirus positivity was apparent. Third, poorer countries may report lower proportions of rotavirus disease because of increased prevalence of other enteric pathogens, even though the incidence of hospitalizations for rotavirus infection may be the same. Lastly, rotavirus activity is inherently variable over time and place. Data from similar surveillance in Asia also found a relatively wide range in the incidence of rotavirus infection [16] . For instance, Korea and Japan, 2 high-income countries, reported 20% and 58%, respectively, of hospitalizations attributable to rotavirus during overlapping periods [17, 18] .
Because of this variability in surveillance data, it can be chal- lenging to draw meaningful conclusions from comparisons with other regions or countries. However, overall, the median estimate of the rate of rotavirus infection in the Latin American and Caribbean region of 31.5% (although not the mean of 41%) was lower than global estimates for high-middle-income countries (38%) [19] . The range of the incidence of rotavirus infection found in this study was also consistent with the ranges reported from other regions [16] . Of note, our median incidence of rotavirus infection (31.5%; range, 24%-47%) is similar to findings reported in a review of studies in Latin America that was performed in the 1990s (median, 31%; range, 16%-52%) [6] . Rotavirus transmission in most Latin American countries seems to peak during the winter months. It remains unclear which factors drive seasonality, but lower temperature and relative humidity have been hypothesized as important [20] , because these may prolong virus survival on fomites [21] . We observed a strong seasonality in Central America, Venezuela, and Guyana that was contrary to previous reports that suggested that tropical countries exhibited little apparent seasonality of rotavirus disease [22] . Analysis of seasonality in each individual country will help show how vaccine introduction will affect the epidemiology of rotavirus.
Our surveillance system and subsequent data analysis has several limitations. First, we were only able to present aggregated data and were not able to provide more-detailed information on age, history of vaccination, and other risk factors for rotavirus infection. Second, we only present data for 1 or 2 full years, which may not be representative. This also has special significance for assessing genotype variations, because the prevalence of genotypes can vary annually. Third, selection biases, such as exclusion of children who met the case definition but had clinical features suggestive of nonrotavirus etiologies, cannot be ruled out. Finally, although 3 countries in the network introduced rotavirus vaccine during the surveillance period, we were not able to demonstrate an impact of vaccine introduction in the 2 countries for which we had data (El Salvador and Venezuela). In these 3 countries, vaccine was introduced only for children aged !6 months, with no catch-up campaigns, and did not reach high coverage during the first year of vaccination [5] . We anticipate that ongoing surveillance will soon provide sufficient data to allow a breakdown by age to examine the effect that vaccination may have had on the incidence of rotavirus infection. The rotavirus surveillance network in Latin American and Caribbean countries differs from previous studies on rotavirus in the region, because country Ministries of Health maintain ownership and responsibility for coordination and management. Such ownership hopefully will translate into a more sustained approach to provide robust longitudinal data on rotavirus. These data also will more likely be incorporated in evidence-based decision-making on vaccine introduction. Furthermore, this platform will allow for further work, such as cost-effectiveness studies. Pre-introduction surveillance data will also facilitate the assessment of the impact of rotavirus vaccination after introduction, particularly considering changes in frequency, severity of disease, and circulating genotypes. Surveillance data has been used in the United States to detect a decrease in the incidence of rotavirus infection that was larger than expected to result from vaccination alone, suggesting some herd or indirect vaccination effect [23] . Such effect in Latin American and Caribbean countries can only be identified by maintaining robust surveillance systems with careful monitoring of the quality of surveillance methods, data collection, and results.
